secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001437749-22-025458
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pieris Q3 net loss $9.7M ($0.13/sh); cash at $69.8M, funded into Q2 2024
------------------------------------------------------------------------

- Net loss of $9.7M ($0.13 per share) vs $16.5M ($0.24) in Q3 2021.
- Cash and investments $69.8M at Sept 30, down from $117.8M at Dec 31, 2021; company expects funding into Q2 2024.
- R&D expense $13.6M (down from $18.9M); G&A $3.9M (down from $4.1M).
- Elarekibep Phase 2a asthma study enrollment continues; topline FEV1 results expected by Q3 2023.
- PRS-220 Phase 1 first subject dosed; IND accepted for SGN-BB228; PRS-342 Phase 1 start within 6 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000143774922025458/0001437749-22-025458-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000143774922025458/pirs20220831_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-025458

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer